FAQs

Frequently Asked Questions

1What does Caladrius do?
Caladrius is an immune therapy development company with a unique expertise and experience in cell process development, optimization and manufacturing. We are a new breed of company in an exciting emerging therapy area with a proprietary platform that enables us to bring unique and better solutions directly to market through partnerships. See our ‘About Us’ page for more information.
2What is Caladrius’ relationship with PCT?
PCT, a Caladrius Company, is a wholly-owned subsidiary of Caladrius Biosciences. Caladrius acquired PCT in January 2011.
3What is Caladrius’ Financial Conflict of Interest Policy?
You can view the Company’s Financial Conflict of Interest Policy by clicking here.
4What is Caladrius’ ticker symbol, exchange and CUSIP?
The Company’s common stock is traded on NASDAQ, ticker symbol CLBS. The CUSIP for the common stock is 128058104.
5What is Caladrius’ fiscal year?
Caladrius’ fiscal year ends on December 31.
6Who is Caladrius’ IR contact?
Caladrius Biosciences Inc.
Eric Powers
Phone: (212) 584-4173
E-mail: epowers@caladrius.com
7Who are Caladrius’ auditor and corporate legal counsel?
Caladrius’ auditor is Grant Thornton LLP. (www.granthornton.com) Caladrius’ corporate legal counsel is Paul Hastings LLP. (www.paulhastings.com)
8Who is Caladrius’ transfer agent?
Caladrius’ transfer agent is Continental Stock Transfer & Trust Company (www.continentalstock.com)